You are here

Article info

Article menu

Download PDFPDF

XML
Review
Master protocols in immuno-oncology: do novel drugs deserve novel designs?

Authors

  • Luca Mazzarella Division of Early Drug Development for Innovative Therapies, IEO European Institute of Oncology IRCCS, Milan, Italy Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy PubMed articlesGoogle scholar articles
  • Stefania Morganti Division of Early Drug Development for Innovative Therapies, IEO European Institute of Oncology IRCCS, Milan, Italy PubMed articlesGoogle scholar articles
  • Antonio Marra Division of Early Drug Development for Innovative Therapies, IEO European Institute of Oncology IRCCS, Milan, Italy PubMed articlesGoogle scholar articles
  • Dario Trapani Division of Early Drug Development for Innovative Therapies, IEO European Institute of Oncology IRCCS, Milan, Italy PubMed articlesGoogle scholar articles
  • Giulia Tini Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy PubMed articlesGoogle scholar articles
  • Piergiuseppe Pelicci Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy Department of Oncology and Hematology, Universita degli Studi di Milano, Milan, Italy PubMed articlesGoogle scholar articles
  • Giuseppe Curigliano Division of Early Drug Development for Innovative Therapies, IEO European Institute of Oncology IRCCS, Milan, Italy Department of Oncology and Hematology, Universita degli Studi di Milano, Milan, Italy PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Luca Mazzarella; luca.mazzarella{at}ieo.it
View Full Text

Citation

Mazzarella L, Morganti S, Marra A, et al
Master protocols in immuno-oncology: do novel drugs deserve novel designs?
Journal for ImmunoTherapy of Cancer 2020;8:e000475. doi: 10.1136/jitc-2019-000475

Publication history

  • Accepted March 14, 2020
  • First published April 1, 2020.
Online issue publication 
January 11, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.